Letter

Patients taking selegiline may have received more levodopa than necessary

BMJ 1996; 312 doi: 10.1136/bmj.312.7032.702a (Published 16 March 1996)
Cite this as: BMJ 1996;312:702.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. C Warren Olanow*,
  2. James H Godbold**,
  3. William Koller*
  1. Professor, department of neurology Research associate professor, department of community medicine Mount Sinai Medical Center, Box 1137, New York, NY 10029, USA
  2. Professor Department of Neurology, University of Kansas, Kansas City, KS 66160, USA

    EDITOR,—The Parkinson's Disease Research Group reports a 60% increase in mortality over five years in patients with Parkinson's disease taking levodopa and selegiline compared with those taking levodopa alone.1 This is the first report of increased mortality with selegiline and contrasts with our experience.2 We performed a prospective double blind study in 101 comparable patients with Parkinson's disease. They were randomly assigned to receive selegiline or placebo plus levodopa or bromocriptine. After five years only eight deaths had occurred (five in patients taking placebo and three in patients taking selegiline).

    We have several concerns with …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular